دورية أكاديمية
Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19
العنوان: | Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19 |
---|---|
المؤلفون: | Garcia-Rios, Estefani, Leivas, Alejandra, Mancebo, Francisco Jose, Sánchez-Vega, Laura, Lanzarot, Diego, Aguado, José María, Martinez-Lopez, Joaquin, Paciello, María Liz, Perez-Romero, Pilar |
المساهمون: | RETICS-Investigación en Patología Infecciosa (REIPI-ISCIII) (España), Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Unión Europea. Fondo Social Europeo (ESF/FSE), Ministerio de Ciencia, Innovación y Universidades (España), Ministerio de Ciencia e Innovación (España), Plan Nacional de I+D+i (España), Instituto de Salud Carlos III, Comunidad de Madrid (España), Fundación Mutua Madrileña |
بيانات النشر: | Multidisciplinary Digital Publishing Institute (MDPI) |
سنة النشر: | 2022 |
المجموعة: | REPISALUD (REPositorio Institucional en SALUD del Instituto de Salud Carlos III - ISCIII) |
مصطلحات موضوعية: | SARS-CoV-2, T-lymphocytes, Cytotoxicity, M protein |
الوصف: | In order to demonstrate the feasibility of preparing clinical-grade SARS-CoV-2-specific T-cells from convalescent donors and the ability of these cells to neutralize the virus in vitro, we used blood collected from two COVID-19 convalescent donors (before and after vaccination) that was stimulated with specific SARS-CoV-2 peptides followed by automated T-cell isolation using the CliniMacs Prodigy medical device. To determine cytotoxic activity, HEK 293T cells were transfected to express the SARS-CoV-2 M protein, mimicking SARS-CoV-2 infection. We were able to quickly and efficiently isolate SARS-CoV-2-specific T lymphocytes from both donors before and after they received the Pfizer-BioNTech vaccine. Althoughbefore vaccination, the final product contained up to 7.42% and 30.19% of IFN-γ+ CD3+ T-cells from donor 1 and donor 2, respectively, we observed an enrichment of the IFN-γ+ CD3+ T-cells after vaccination, reaching 70.47% and 42.59%, respectively. At pre-vaccination, the isolated SARS-CoV-2-specific T-cells exhibited cytotoxic activity that was significantly higher than that of unstimulated controls (donor 2: 15.41%, p-value 3.27 × 10-3). The cytotoxic activity of the isolated SARS-CoV-2-specific T-cells also significantly increased after vaccination (donor 1: 32.71%, p-value 1.44 × 10-5; donor 2: 33.38%, p-value 3.13 × 10-6). In conclusion, we demonstrated that SARS-CoV-2-specific T-cells can quickly and efficiently be stimulated from the blood of convalescent donors using SARS-CoV-2-specific peptides followed by automated isolation. Vaccinated convalescent donors have a higher percentage of SARS-CoV-2-specific T-cells and may be more suitable as donors. Although further studies are needed to assess the clinical utility of the functional isolated SARS-CoV-2-specific T-cells in patients, previous studies using the same stimulation and isolation methods applied to other pathologies support this idea. ; This work was supported by MutuaMadrileña Foundation (2020/0056), “Plan Nacional de I+D+I” and Instituto de ... |
نوع الوثيقة: | article in journal/newspaper |
اللغة: | English |
تدمد: | 2227-9059 |
العلاقة: | https://doi.org/10.3390/biomedicines10030630Test; info:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0004/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/; info:eu-repo/grantAgreement/ES/COV20/00181; info:eu-repo/grantAgreement/ES/CD18CIII/00007; info:eu-repo/grantAgreement/ES/F18III/00013; Biomedicines. 2022 Mar 9;10(3):630.; http://hdl.handle.net/20.500.12105/14481Test; Biomedicines |
DOI: | 10.3390/biomedicines10030630 |
الإتاحة: | https://doi.org/20.500.12105/14481Test https://doi.org/10.3390/biomedicines10030630Test https://hdl.handle.net/20.500.12105/14481Test |
حقوق: | http://creativecommons.org/licenses/by/4.0Test/ ; Atribución 4.0 Internacional ; open access |
رقم الانضمام: | edsbas.32924AFC |
قاعدة البيانات: | BASE |
تدمد: | 22279059 |
---|---|
DOI: | 10.3390/biomedicines10030630 |